查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1756395

基因编辑治疗市场，按技术、按开发阶段、按治疗类型、按疾病适应症、按最终用户、按国家/地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额及预测

Gene Editing Therapeutics Market, By Technology, By Development Stage, By Therapy Type, By Disease Indication, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年基因编辑治疗市场规模价值为 1,113 万美元，2025 年至 2032 年的复合年增长率为 147.20%。

基因编辑治疗市场-市场动态

突破性临床审批和精准工具助力促进治疗应用

突破性的临床审批和精准工具正在显着推动全球基因编辑疗法的应用。美国食品药物管理局 (FDA) 于 2023 年批准了首个基于 CRISPR 的镰状细胞疾病疗法，该疗法由 Vertex Pharmaceuticals 和 CRISPR Therapeutics 合作开发，标誌着基因编辑向临床应用迈出了历史性的一步。同时，美国国立卫生研究院 (NIH) 增加了对精准基因组工程研究的资助，推广碱基编辑和主要编辑等工具，以纠正突变并减少脱靶效应。在英国，药品和保健产品监管局 (MHRA) 已启动基因编辑疗法的加速审查途径，旨在更快地为患者带来先进的治疗方法。这些发展反映出全球日益重视基因编辑的安全、高效和可扩展的治疗应用，增强了其改变遗传性疾病、癌症和复杂疾病治疗的潜力。

基因编辑治疗市场—关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场年复合成长率预计约为 147.20%。

根据技术细分，预计 CRISPR 将在 2024 年占据最大市场份额

根据开发阶段细分，临床前是 2024 年领先的开发阶段

根据治疗类型细分，体外基因编辑是 2024 年领先的治疗类型

根据疾病适应症细分，遗传性疾病是 2024 年的主要疾病适应症

根据最终用户细分，生物製药公司是 2024 年领先的最终用户

按地区划分，北美是 2024 年的主要收入来源

基因编辑治疗市场-細項分析：

全球基因编辑治疗市场根据技术、开发阶段、治疗类型、疾病适应症、最终用户和地区进行细分。

根据技术，市场分为五类：CRISPR、ZFN、TALEN、碱基编辑和RNA编辑。 CRISPR因其简单高效而处于领先地位；ZFN具有特异性，但设计复杂；TALEN因其在基因敲除研究中的精准靶向性而受到重视；碱基编辑可实现单核苷酸改变；RNA编辑可在不改变DNA的情况下进行瞬时修饰。

根据开发阶段，市场分为五类：临床前、I期、II期、III期和已获批准。临床前阶段占主导地位，众多候选药物正在研究中；I期侧重于安全性分析；II期探索治疗效果；III期涉及跨人群的大规模验证；已获批准的疗法标誌着从研究阶段到受监管治疗阶段的成功过渡，在罕见遗传疾病领域日益受到关注。

基因编辑治疗市场—地理洞察

基因编辑治疗市场表现出强劲的区域活力，其中北美由于其先进的生物技术基础设施、广泛的临床研究活动以及来自 FDA 等机构的支持性监管框架而处于领先地位。美国在基于 CRISPR 的疗法的审批和试验方面处于领先地位，这得益于大量公共和私人资金的支持。欧洲紧随其后，英国、德国和瑞士等国家正积极投资精准医疗，EMA 等监管机构对创新基因治疗的接受度也越来越高。亚太地区正在获得发展动力，尤其是在中国和日本，政府措施和生物技术合作正在加速基因编辑研究。中国积极参与临床试验和监管改革正在帮助塑造竞争格​​局。拉丁美洲和中东及非洲正在透过学术合作伙伴关係和试点计画逐步进入该领域，重点是能力建立和调整监管模式以适应未来的基因治疗整合。

基因编辑治疗市场-竞争格局：

基因编辑治疗市场的竞争格局由许多生技公司、製药公司和学术研究机构共同塑造，他们致力于推动安全有效的基因编辑疗法。领先的参与者正在积极开发基于 CRISPR、TALEN 和锌指核酸酶 (ZFN) 的疗法，以治疗多种遗传疾病和慢性疾病。生技新创公司与大型製药公司之间的合作日益普遍，旨在加速临床开发和监管审批。显着的进展包括合作开发基于 CRISPR 的血液疾病疗法和用于癌症的 CAR-T 细胞工程。学术机构也发挥着至关重要的作用，为早期研究和工具改进做出了贡献，这些工具随后被授权用于治疗用途。独家授权协议、拓展国际市场以及投资符合 GMP 标准的生产设施等策略性倡议正成为获得竞争优势的关键，其中重点是开发个人化和治癒性疗法。

最新动态：

2025 年 5 月，CRISPR Therapeutics 和 Sirius Therapeutics 宣布进行多目标合作，开发新型 siRNA 疗法，包括用于治疗血栓栓塞性疾病的 SRSD107，旨在实现一流的、长效的基因治疗，减少给药频率并改善患者的治疗效果。

2025年5月，美国国立卫生研究院（NIH）资助的研究人员为一名患有CPS1缺陷的婴儿进行了首例个人化CRISPR基因编辑疗法。该疗法利用一个快速、可自订的平台，在六个月内纠正了肝细胞中的基因缺陷，标誌着罕见疾病治疗领域的突破。

2023年11月，Vertex和CRISPR Therapeutics获得了全球首个基于CRISPR的镰状细胞疾病和β地中海贫血基因编辑疗法的授权，这是基因编辑疗法的历史性里程碑，为患有这些遗传疾病的患者带来了新的希望。

目录

第一章：基因编辑治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 基因编辑治疗市场技术片段
    • 基因编辑治疗市场依发展阶段划分
    • 基因编辑治疗市场片段（按治疗类型）
    • 基因编辑治疗市场片段（按疾病适应症）
    • 基因编辑治疗市场片段（按最终用户）
    • 基因编辑治疗市场（按国家/地区）
    • 基因编辑治疗市场按地区划分
  • 竞争洞察

第三章：基因编辑治疗的关键市场趋势

  • 基因编辑治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 基因编辑治疗市场限制
    • 市场限制的影响分析
  • 基因编辑治疗市场机会
  • 基因编辑治疗市场未来趋势

第四章：基因编辑治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：基因编辑治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：基因编辑治疗市场格局

  • 2024年基因编辑治疗市占分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：基因编辑治疗市场 - 依技术

  • 概述
    • 按技术细分的市场份额分析
    • CRISPR
    • 锌指蛋白
    • 塔伦
    • 碱基编辑
    • RNA编辑

第 8 章：基因编辑治疗市场 - 依发展阶段

  • 概述
    • 按开发阶段分類的细分市场占有率分析
    • 临床前
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 得到正式认可的

第九章：基因编辑治疗市场－依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 体内基因编辑
    • 体外基因编辑

第 10 章：基因编辑治疗市场 - 依疾病适应症

  • 概述
    • 按疾病适应症分類的细分份额分析
    • 血液系统疾病
    • 遗传性疾病（例如镰状细胞疾病、杜氏肌肉营养不良症）
    • 癌症
    • 传染病
    • 眼部疾病

第 11 章：基因编辑治疗市场 - 按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院
    • 专科诊所
    • 研究机构
    • 生物製药公司

第 12 章：基因编辑治疗市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美基因编辑治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按技术）
    • 北美市场规模与预测，依发展阶段
    • 北美市场规模和预测，按治疗类型
    • 北美市场规模及预测（依疾病类型划分）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲基因编辑治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模与预测（按技术）
    • 欧洲市场规模及预测（依发展阶段）
    • 欧洲市场规模及预测（按治疗类型）
    • 欧洲市场规模及预测（依疾病类型划分）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区基因编辑治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依技术）
    • 亚太地区市场规模及预测（依发展阶段）
    • 亚太地区市场规模及预测（依治疗类型）
    • 亚太地区市场规模及预测（依疾病类型划分）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲基因编辑治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按技术）
    • 拉丁美洲市场规模及预测（依发展阶段）
    • 拉丁美洲市场规模及预测（按治疗类型）
    • 拉丁美洲市场规模及预测（依疾病类型划分）
    • LATAM 规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲基因编辑治疗主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（按技术）
    • 中东及非洲市场规模及预测（依发展阶段）
    • 中东和非洲市场规模及预测（按治疗类型）
    • 中东和非洲市场规模及预测（按疾病类型划分）
    • 中东和非洲市场规模及预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 13 章：基因编辑治疗产业主要供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • ArsenalBio
    • Beam Therapeutics
    • Caribou Biosciences
    • CRISPR Therapeutics
    • Editas Medicine
    • EditForce
    • Excision BioTherapeutics
    • Graphite Bio
    • Homology Medicines
    • Intellia Therapeutics
    • LogicBio Therapeutics
    • Poseida Therapeutics
    • Precision BioSciences
    • Recombinetics
    • Sangamo Therapeutics
    • Verve Therapeutics
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5349

REPORT HIGHLIGHT

Gene Editing Therapeutics Market size was valued at US$ 11.13 Million in 2024, expanding at a CAGR of 147.20% from 2025 to 2032.

The Gene Editing Therapeutics Market centers on the development and commercialization of treatments that correct or modify genetic mutations at the DNA level to treat or potentially cure diseases. With increasing approvals for gene-editing therapies in rare and inherited disorders, the market is expanding into oncology and infectious diseases. In 2023, the U.S. FDA approved the first CRISPR-based therapy for sickle cell anemia, marking a major milestone in clinical gene editing. Technological innovations like base editing and prime editing are enhancing precision while minimizing off-target effects, making gene-editing tools safer for therapeutic use. However, high treatment costs, ethical concerns, and complex regulatory pathways continue to pose significant challenges to widespread adoption. Opportunities exist in the development of personalized medicine, targeting previously untreatable conditions, and expanding gene editing to common diseases, supported by increasing research funding from national health agencies and global biotech collaborations.

Gene Editing Therapeutics Market- Market Dynamics

Breakthrough clinical approvals and precision tools to boost therapeutic adoption

Breakthrough clinical approvals and precision tools are significantly boosting the adoption of gene editing therapeutics worldwide. The U.S. FDA's 2023 approval of the first CRISPR-based therapy for sickle cell disease, developed in partnership with Vertex Pharmaceuticals and CRISPR Therapeutics, marked a historic shift toward clinical application of gene editing. Simultaneously, the National Institutes of Health (NIH) has increased funding for precision genome engineering research, promoting tools like base editing and prime editing to correct mutations with fewer off-target effects. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has initiated accelerated review pathways for gene-editing therapies, aiming to bring advanced treatments to patients faster. These developments reflect a growing global emphasis on safe, efficient, and scalable therapeutic applications of gene editing, reinforcing its potential to transform the treatment of inherited disorders, cancers, and complex diseases.

Gene Editing Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 147.20% over the forecast period (2025-2032)

Based on Technology segmentation, CRISPR was predicted to show maximum market share in the year 2024

Based on Development Stage segmentation, Preclinical was the leading Development Stage in 2024

Based on Therapy Type segmentation, Ex Vivo Gene Editing was the leading Therapy Type in 2024

Based on Disease Indication segmentation, Genetic Disorders were the leading Disease Indication in 2024

Based on end user segmentation, Biopharma Companies was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Gene Editing Therapeutics Market- Segmentation Analysis:

The Global Gene Editing Therapeutics Market is segmented on the basis of Technology, Development Stage, Therapy Type, Disease Indication, End User, and Region.

The market is divided into five categories based on Technology: CRISPR, ZFN, TALEN, Base Editing, and RNA Editing. CRISPR leads due to its simplicity and high efficiency; ZFN offers specificity but requires complex design; TALEN is valued for targeting precision in gene knockout studies; base editing enables single-nucleotide changes; RNA editing allows transient modifications without altering DNA.

The market is divided into five categories based on Development Stage: Preclinical, Phase I, Phase II, Phase III, and Approved. Preclinical dominates with numerous candidates under investigation; Phase I focuses on safety profiling; Phase II explores therapeutic efficacy; Phase III involves large-scale validation across populations; Approved therapies mark successful transition from research to regulated treatment, gaining traction in rare genetic disorders.

Gene Editing Therapeutics Market- Geographical Insights

The Gene Editing Therapeutics Market exhibits strong regional dynamics, with North America at the forefront due to advanced biotech infrastructure, extensive clinical research activity, and supportive regulatory frameworks from agencies like the FDA. The U.S. leads in approvals and trials for CRISPR-based therapies, reinforced by substantial public and private funding. Europe follows closely, where countries such as the UK, Germany, and Switzerland are actively investing in precision medicine, and regulatory bodies like the EMA are increasingly receptive to innovative genetic treatments. The Asia-Pacific region is gaining traction, particularly in China and Japan, where government initiatives and biotech collaborations are accelerating gene editing research. China's active involvement in clinical trials and regulatory reforms is helping shape a competitive landscape. Latin America and the Middle East & and Africa are gradually entering the space through academic partnerships and pilot programs, focusing on capacity building and adapting regulatory models for future gene therapy integration.

Gene Editing Therapeutics Market- Competitive Landscape:

The competitive landscape of the Gene Editing Therapeutics Market is shaped by a mix of biotechnology firms, pharmaceutical companies, and academic research institutions striving to advance safe and effective gene-editing therapies. Leading players are actively developing CRISPR, TALEN, and zinc finger nuclease (ZFN)-based treatments, targeting a wide range of genetic and chronic diseases. Collaborations between biotech startups and large pharmaceutical companies are increasingly common, aimed at accelerating clinical development and regulatory approval. Notable advancements include partnerships to co-develop CRISPR-based therapies for blood disorders and CAR-T cell engineering for cancer. Academic institutions also play a vital role, contributing to early-stage research and tool refinement, which are later licensed for therapeutic use. Strategic initiatives such as exclusive licensing agreements, expansion into international markets, and investment in GMP-compliant manufacturing facilities are becoming central to gaining a competitive advantage, with a strong focus on developing personalized and curative therapies.

Recent Developments:

In May 2025, CRISPR Therapeutics and Sirius Therapeutics have announced a multi-target collaboration to develop novel siRNA therapies, including SRSD107 for thromboembolic disorders, aiming for best-in-class, long-acting gene-based treatments with infrequent dosing and improved patient outcomes.

In May 2025, NIH-supported researchers delivered the first personalized CRISPR gene-editing therapy to an infant with CPS1 deficiency. Using a rapid, customizable platform, the treatment corrected the genetic defect in liver cells within six months, marking a breakthrough for rare disease therapeutics.

In November 2023, Vertex and CRISPR Therapeutics received authorization for the world's first CRISPR-based gene editing therapy for sickle cell disease and beta thalassemia, marking a historic milestone in gene editing therapeutics and offering new hope for patients with these genetic disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENE EDITING THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • ArsenalBio
  • Beam Therapeutics
  • Caribou Biosciences
  • CRISPR Therapeutics
  • Editas Medicine
  • EditForce
  • Excision BioTherapeutics
  • Graphite Bio
  • Homology Medicines
  • Intellia Therapeutics
  • LogicBio Therapeutics
  • Poseida Therapeutics
  • Precision BioSciences
  • Recombinetics
  • Sangamo Therapeutics
  • Verve Therapeutics
  • Others

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • CRISPR
  • ZFN
  • TALEN
  • Base Editing
  • RNA Editing

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2019 - 2032

  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Approved

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • In Vivo Gene Editing
  • Ex Vivo Gene Editing

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Hematologic Disorders
  • Genetic Disorders (e.g., Sickle Cell, DMD)
  • Cancer
  • Infectious Diseases
  • Eye Disorders

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Research Organizations
  • Biopharma Companies

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gene Editing Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gene Editing Therapeutics Market Snippet by Technology
    • 2.1.2. Gene Editing Therapeutics Market Snippet by Development Stage
    • 2.1.3. Gene Editing Therapeutics Market Snippet by Therapy Type
    • 2.1.4. Gene Editing Therapeutics Market Snippet by Disease Indication
    • 2.1.5. Gene Editing Therapeutics Market Snippet by End User
    • 2.1.6. Gene Editing Therapeutics Market Snippet by Country
    • 2.1.7. Gene Editing Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Gene Editing Therapeutics Key Market Trends

  • 3.1. Gene Editing Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gene Editing Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gene Editing Therapeutics Market Opportunities
  • 3.4. Gene Editing Therapeutics Market Future Trends

4. Gene Editing Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gene Editing Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gene Editing Therapeutics Market Landscape

  • 6.1. Gene Editing Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gene Editing Therapeutics Market - By Technology

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 7.1.2. CRISPR
    • 7.1.3. ZFN
    • 7.1.4. TALEN
    • 7.1.5. Base Editing
    • 7.1.6. RNA Editing

8. Gene Editing Therapeutics Market - By Development Stage

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Development Stage, 2024 & 2032 (%)
    • 8.1.2. Preclinical
    • 8.1.3. Phase I
    • 8.1.4. Phase II
    • 8.1.5. Phase III
    • 8.1.6. Approved

9. Gene Editing Therapeutics Market - By Therapy Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
    • 9.1.2. In Vivo Gene Editing
    • 9.1.3. Ex Vivo Gene Editing

10. Gene Editing Therapeutics Market - By Disease Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 10.1.2. Hematologic Disorders
    • 10.1.3. Genetic Disorders (e.g., Sickle Cell, DMD)
    • 10.1.4. Cancer
    • 10.1.5. Infectious Diseases
    • 10.1.6. Eye Disorders

11. Gene Editing Therapeutics Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Specialty Clinics
    • 11.1.4. Research Organizations
    • 11.1.5. Biopharma Companies

12. Gene Editing Therapeutics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gene Editing Therapeutics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gene Editing Therapeutics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gene Editing Therapeutics Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Gene Editing Therapeutics Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gene Editing Therapeutics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gene Editing Therapeutics Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. ArsenalBio
    • 13.2.2. Beam Therapeutics
    • 13.2.3. Caribou Biosciences
    • 13.2.4. CRISPR Therapeutics
    • 13.2.5. Editas Medicine
    • 13.2.6. EditForce
    • 13.2.7. Excision BioTherapeutics
    • 13.2.8. Graphite Bio
    • 13.2.9. Homology Medicines
    • 13.2.10. Intellia Therapeutics
    • 13.2.11. LogicBio Therapeutics
    • 13.2.12. Poseida Therapeutics
    • 13.2.13. Precision BioSciences
    • 13.2.14. Recombinetics
    • 13.2.15. Sangamo Therapeutics
    • 13.2.16. Verve Therapeutics
    • 13.2.17. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us